CTOs on the Move

Polar Electro Inc

www.polarusa.com

 
Polar Electro Inc is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.polarusa.com
  • 1111 Marcus Ave Ste m15
    New Hyde Park, NY USA 11042
  • Phone: 516.364.0400

Executives

Name Title Contact Details

Similar Companies

Eleven Therapeutics

Eleven Therapeutics is at the forefront of mRNA therapeutics innovation, harnessing combinatorial chemistry, synthetic biology, and artificial intelligence to develop next-generation therapies. The company`s pipeline includes extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. Proprietary high-throughput screening platforms, TERA™ and DELiveri™, underpin Eleven Therapeutics` pipeline by generating chemically modified xRNAs and cell-penetrating delivery carriers. Founded in 2020 by world-leading scientists across Cambridge (UK), Boston (US), and Tel Aviv (Israel), Eleven Therapeutics is supported by top-tier venture capitalists and the Bill & Melinda Gates Foundation.

Nuvelo

Nuvelo, Inc. is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angstrom Scientific

Angstrom Scientific is a Ramsey, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evelo Biosciences

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo`s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering`s institutional innovation foundry, and launched by Flagship in 2015.